'Simply stunning' - Trastuzumab in HER2-positive breast cancer

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 5, 2006, Pages 631-634

  Doggrell, Sheila A ^a  

^a CHARLES DARWIN UNIVERSITY   (Australia)

Author keywords

Anthracyclines; Cyclophosphamide; HER 2 positive metastatic breast cancer; Paclitaxel; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; DRUG USE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; METASTASIS; PATIENT MONITORING;

EID: 33645804772     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.5.631     Document Type: Article

References (6)

1. SALMON DJ, LEYLAND-JONES B, SHAK T et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N. Engl. J. Med. (2001) 344:783-792.
2. VOGEL CL, COBLEIGH MA, TRIPATHY D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. (2002) 20:719-726.
3. PEGRAM MD, PIENKOWSKI T, NORTHFELT DW et al.: Results of two open-label, multicenter Phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J. Natl. Cancer Inst. (2004) 96:759-769.
4. ROMOND EH, PEREZ EA, BRYANT J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. (2005) 353:1673-1684.
5. PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353:1659-1672.
6. HORTOBAGYI GN: Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. (2005) 353:1734-1736.